Skip to main content

09-01-2021 | Dementia | News

News in brief

Telmisartan linked to reduced dementia risk in people with type 2 diabetes, hypertension

Author: Alba Ruzafa


medwireNews: Study results suggest that telmisartan use in people with concomitant type 2 diabetes and hypertension is associated with a lower incidence of dementia and ischemic stroke compared with the use of other angiotensin receptor blockers (ARBs).

In their analysis of electronic health records of the National Health Insurance Research Database of Taiwan between 1997 and 2013, the authors observed that after almost 5 years of follow-up, 2.19% of the 2280 individuals receiving telmisartan and 3.20% of the 9120 propensity score-matched individuals receiving other ARBs were diagnosed with dementia. These findings translated into a significantly lower risk in the telmisartan group, at hazard ratio (HR) of 0.72.

Yi-Chia Wei, from National Yang Ming Chiao Tung University in Taipei, Taiwan, and colleagues report similar results when the analysis was restricted to individuals without a stroke diagnosis prior to their dementia diagnosis, and when considering all-cause mortality as a competing factor, at HRs of 0.70 and 0.71, respectively.

Wei et al also add that people using telmisartan were significantly less likely to experience any ischemic stroke events than people using other ARBs, at an HR of 0.79.

“Although our results provide potential clinical evidence to show an association of telmisartan with dementia risk reduction, further studies are warranted to clarify the causal relationship of such therapy and the underlying mechanisms of action,” concludes the team in PLOS Medicine.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

PLoS Med 2021; 18: e1003707


Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video